End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
0.86 PLN | -7.53% | -7.53% | -34.85% |
Feb. 14 | Mycodern S.A. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 | CI |
Feb. 14 | Mycodern S.A. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Valuation
Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
---|---|---|---|---|---|---|
Capitalization 1 | 2.394 | 3.457 | 3.103 | 5.23 | 21.99 | 16.76 |
Enterprise Value (EV) 1 | 2.442 | 3.689 | 2.898 | 5.299 | 21.99 | 17.86 |
P/E ratio | 14 x | 22.5 x | 4.77 x | -18.5 x | -4.41 x | -20.7 x |
Yield | - | - | - | - | - | - |
Capitalization / Revenue | 0.7 x | 1.01 x | 0.38 x | 2.94 x | 2.16 x | 23.5 x |
EV / Revenue | 0.71 x | 1.07 x | 0.36 x | 2.98 x | 2.16 x | 25.1 x |
EV / EBITDA | 12.2 x | 13.9 x | 2.92 x | -108 x | -4.52 x | -25.5 x |
EV / FCF | -23.3 x | -15 x | 11.9 x | 5.64 x | - | - |
FCF Yield | -4.28% | -6.69% | 8.38% | 17.7% | - | - |
Price to Book | 0.54 x | 0.75 x | 0.59 x | 1.05 x | - | 0.63 x |
Nbr of stocks (in thousands) | 8,865 | 8,865 | 8,865 | 8,865 | 8,865 | 8,865 |
Reference price 2 | 0.2700 | 0.3900 | 0.3500 | 0.5900 | 2.480 | 1.890 |
Announcement Date | 6/4/18 | 6/24/19 | 6/26/20 | 5/25/21 | 9/30/22 | 7/7/23 |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
---|---|---|---|---|---|---|
Net sales 1 | 3.422 | 3.437 | 8.112 | 1.78 | 10.18 | 0.7129 |
EBITDA 1 | 0.2009 | 0.2648 | 0.9926 | -0.0491 | -4.866 | -0.6998 |
EBIT 1 | 0.0933 | 0.1537 | 0.8555 | -0.2563 | -5.001 | -0.8352 |
Operating Margin | 2.73% | 4.47% | 10.55% | -14.4% | -49.13% | -117.15% |
Earnings before Tax (EBT) 1 | 0.2407 | 0.1607 | 0.8212 | -0.2537 | -4.985 | -0.8403 |
Net income 1 | 0.1705 | 0.154 | 0.6501 | -0.2832 | -4.982 | -0.8094 |
Net margin | 4.98% | 4.48% | 8.01% | -15.91% | -48.94% | -113.54% |
EPS 2 | 0.0192 | 0.0174 | 0.0733 | -0.0319 | -0.5620 | -0.0913 |
Free Cash Flow 1 | -0.1046 | -0.2467 | 0.2428 | 0.9391 | - | - |
FCF margin | -3.06% | -7.18% | 2.99% | 52.75% | - | - |
FCF Conversion (EBITDA) | - | - | 24.47% | - | - | - |
FCF Conversion (Net income) | - | - | 37.36% | - | - | - |
Dividend per Share | - | - | - | - | - | - |
Announcement Date | 6/4/18 | 6/24/19 | 6/26/20 | 5/25/21 | 9/30/22 | 7/7/23 |
Balance Sheet Analysis
Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
---|---|---|---|---|---|---|
Net Debt 1 | 0.05 | 0.23 | - | 0.07 | - | 1.11 |
Net Cash position 1 | - | - | 0.2 | - | - | - |
Leverage (Debt/EBITDA) | 0.2428 x | 0.8729 x | - | -1.395 x | - | -1.581 x |
Free Cash Flow 1 | -0.1 | -0.25 | 0.24 | 0.94 | - | - |
ROE (net income / shareholders' equity) | 3.9% | 3.39% | 13.2% | -5.53% | -200% | -6.07% |
ROA (Net income/ Total Assets) | 1.06% | 1.44% | 7.96% | -2.69% | - | - |
Assets 1 | 16.06 | 10.66 | 8.171 | 10.53 | - | - |
Book Value Per Share 2 | 0.5000 | 0.5200 | 0.5900 | 0.5600 | - | 3.010 |
Cash Flow per Share 2 | 0.0400 | 0.0100 | 0.0200 | 0.0300 | - | 0.0400 |
Capex 1 | 0.14 | 0.21 | 0.02 | 0.02 | 0.01 | - |
Capex / Sales | 4.19% | 6.19% | 0.25% | 0.9% | 0.13% | - |
Announcement Date | 6/4/18 | 6/24/19 | 6/26/20 | 5/25/21 | 9/30/22 | 7/7/23 |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
1st Jan change | Capi. | |
---|---|---|
-34.85% | 14.25M | |
-2.94% | 274B | |
-1.37% | 96.26B | |
-2.04% | 44.31B | |
+11.44% | 42.37B | |
+1.23% | 41.57B | |
+8.21% | 39.88B | |
-14.26% | 30.97B | |
-6.54% | 29.04B | |
+14.87% | 25.19B |
- Stock Market
- Equities
- MCD Stock
- Financials Mycodern S.A.